FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1974903457> ?p ?o ?g. }

• W1974903457 endingPage "1352" @default.
• W1974903457 startingPage "1346" @default.
• W1974903457 abstract "Tumor necrosis factor alpha (TNFalpha) has been detected in sacroiliac joint biopsy specimens from patients with spondylarthropathy. The present open pilot study was undertaken to test the efficacy of the anti-TNFalpha monoclonal antibody infliximab in the treatment of active ankylosing spondylitis (AS).Eleven patients with AS of short duration (median 5 years, range 0.5-13 years) that had been active for at least 3 months (range 3-72 months) were treated with 3 infusions of infliximab (at weeks 0, 2, and 6), in a dosage of 5 mg/kg. Ten of the 11 patients had elevated C-reactive protein (CRP) levels (>6 mg/liter) before treatment; these elevations were known to have had persisted > 1 year in at least 3 patients. The Bath AS Disease Activity Index (BASDAI), the Bath AS Functional Index (BASFI), pain as measured on a visual analog scale, and the Bath AS Metrology Index (BASMI) were assessed. Quality of life was assessed using the Short Form 36 instrument. Laboratory markers of disease activity, including interleukin-6 (IL-6) levels, were determined. Dynamic magnetic resonance imaging (MRI) of the spine was performed in 5 patients.One patient withdrew from the study due to the occurrence of urticarial xanthoma 8 days after the first infusion. At study enrollment, 3 of 5 patients had evidence of spinal inflammation (spondylitis and spondylodiscitis) as detected by MRI; followup MRI 2-6 weeks after the third infusion revealed improvement in 2. Improvement of > or = 50% in activity, function, and pain scores was documented in 9 of 10 patients; the median improvement in the BASDAI after 4 weeks was 70% (range 41-94%). This clear-cut benefit lasted for 6 weeks after the third infusion in 8 of 10 patients. The median CRP level decreased from 15.5 mg/liter (range <6-90.8) to normal, and the median IL-6 level from 12.4 mg/liter (range 0-28.4) to normal (<5). There was improvement in all 9 SF-36 concepts; the improvement was significant for 6 concepts.These data suggest that anti-TNFalpha therapy is very effective for several weeks in AS. Whether this therapy, in addition to its antiinflammatory effect, prevents ankylosis remains to be determined." @default.
• W1974903457 created "2016-06-24" @default.
• W1974903457 creator A5009708454 @default.
• W1974903457 creator A5012794658 @default.
• W1974903457 creator A5020029860 @default.
• W1974903457 creator A5034825662 @default.
• W1974903457 creator A5035876758 @default.
• W1974903457 creator A5052284888 @default.
• W1974903457 creator A5069831361 @default.
• W1974903457 creator A5081920237 @default.
• W1974903457 creator A5085745432 @default.
• W1974903457 date "2000-06-01" @default.
• W1974903457 modified "2023-09-25" @default.
• W1974903457 title "Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximab" @default.
• W1974903457 cites W104232774 @default.
• W1974903457 cites W107430541 @default.
• W1974903457 cites W1966756689 @default.
• W1974903457 cites W1973123086 @default.
• W1974903457 cites W1978655912 @default.
• W1974903457 cites W1985763670 @default.
• W1974903457 cites W1993467896 @default.
• W1974903457 cites W1996472975 @default.
• W1974903457 cites W2020400759 @default.
• W1974903457 cites W2022917163 @default.
• W1974903457 cites W2023780814 @default.
• W1974903457 cites W2027454708 @default.
• W1974903457 cites W2037377025 @default.
• W1974903457 cites W2062338518 @default.
• W1974903457 cites W2065029052 @default.
• W1974903457 cites W2072561199 @default.
• W1974903457 cites W2080334512 @default.
• W1974903457 cites W2091452114 @default.
• W1974903457 cites W2103778140 @default.
• W1974903457 cites W2112391397 @default.
• W1974903457 cites W2123806340 @default.
• W1974903457 cites W2141744584 @default.
• W1974903457 cites W2160367898 @default.
• W1974903457 cites W2167467847 @default.
• W1974903457 cites W2173317407 @default.
• W1974903457 cites W2326330820 @default.
• W1974903457 cites W2336936581 @default.
• W1974903457 cites W2409379695 @default.
• W1974903457 cites W2410687733 @default.
• W1974903457 cites W2419289053 @default.
• W1974903457 cites W2435221055 @default.
• W1974903457 doi "https://doi.org/10.1002/1529-0131(200006)43:6<1346::aid-anr18>3.0.co;2-e" @default.
• W1974903457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10857793" @default.
• W1974903457 hasPublicationYear "2000" @default.
• W1974903457 type Work @default.
• W1974903457 sameAs 1974903457 @default.
• W1974903457 citedByCount "464" @default.
• W1974903457 countsByYear W19749034572012 @default.
• W1974903457 countsByYear W19749034572013 @default.
• W1974903457 countsByYear W19749034572014 @default.
• W1974903457 countsByYear W19749034572015 @default.
• W1974903457 countsByYear W19749034572016 @default.
• W1974903457 countsByYear W19749034572017 @default.
• W1974903457 countsByYear W19749034572018 @default.
• W1974903457 countsByYear W19749034572019 @default.
• W1974903457 countsByYear W19749034572020 @default.
• W1974903457 countsByYear W19749034572021 @default.
• W1974903457 countsByYear W19749034572022 @default.
• W1974903457 countsByYear W19749034572023 @default.
• W1974903457 crossrefType "journal-article" @default.
• W1974903457 hasAuthorship W1974903457A5009708454 @default.
• W1974903457 hasAuthorship W1974903457A5012794658 @default.
• W1974903457 hasAuthorship W1974903457A5020029860 @default.
• W1974903457 hasAuthorship W1974903457A5034825662 @default.
• W1974903457 hasAuthorship W1974903457A5035876758 @default.
• W1974903457 hasAuthorship W1974903457A5052284888 @default.
• W1974903457 hasAuthorship W1974903457A5069831361 @default.
• W1974903457 hasAuthorship W1974903457A5081920237 @default.
• W1974903457 hasAuthorship W1974903457A5085745432 @default.
• W1974903457 hasConcept C126322002 @default.
• W1974903457 hasConcept C141071460 @default.
• W1974903457 hasConcept C14184104 @default.
• W1974903457 hasConcept C17991360 @default.
• W1974903457 hasConcept C2776260265 @default.
• W1974903457 hasConcept C2777138892 @default.
• W1974903457 hasConcept C2777402515 @default.
• W1974903457 hasConcept C2777453003 @default.
• W1974903457 hasConcept C2777575956 @default.
• W1974903457 hasConcept C2779650986 @default.
• W1974903457 hasConcept C2780415856 @default.
• W1974903457 hasConcept C71924100 @default.
• W1974903457 hasConcept C90924648 @default.
• W1974903457 hasConceptScore W1974903457C126322002 @default.
• W1974903457 hasConceptScore W1974903457C141071460 @default.
• W1974903457 hasConceptScore W1974903457C14184104 @default.
• W1974903457 hasConceptScore W1974903457C17991360 @default.
• W1974903457 hasConceptScore W1974903457C2776260265 @default.
• W1974903457 hasConceptScore W1974903457C2777138892 @default.
• W1974903457 hasConceptScore W1974903457C2777402515 @default.
• W1974903457 hasConceptScore W1974903457C2777453003 @default.
• W1974903457 hasConceptScore W1974903457C2777575956 @default.
• W1974903457 hasConceptScore W1974903457C2779650986 @default.
• W1974903457 hasConceptScore W1974903457C2780415856 @default.
• W1974903457 hasConceptScore W1974903457C71924100 @default.

• next